Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
Related Questions
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
Given that high coronary calcium scores portend significantly increased cardiac mortality rates over 5-6 years, is there any data to support performing coronary angiography when the score is very high, e.g. over 1000, even in asymptomatic patients with no objective evidence of ischemia?
Is there any difference between colchicine 0.5mg vs 0.6 mg for high risk coronary artery disease?
In patients with post-MI LV thrombus which resolves after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
How would you proceed with V-A ECMO cannulation (Venous cannula) on a patient with massive PE who has an IVC filter with high thrombus burden?
When do you consider revascularizing Chronic total occlusions after failing medical management?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
How do you approach revascularization in patients over 75 years with NSTEMI, given recent evidence from the SENIOR-RITA trial that an invasive strategy does not significantly reduce cardiovascular events compared to a conservative strategy?
Do you recommend transitioning from ticagrelor-aspirin DAPT to ticagrelor monotherapy after 1 month in patients with acute coronary syndrome and average bleeding risk post-PCI to reduce the risk of bleeding?
